jRCT2031200367
Untitled Trial
A Double blind, Randomized, Placebo controlled Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of Olpasiran (AMG 890) in Subjects With Elevated Lipoprotein(a)
Amgen K.K.·Japan Registry Clinical TrialCompleted
Study focus
- Disease/Condition
- Cardiovascular Disease
- Study type
- Interventional
Sponsor & location
- Primary sponsor
- Amgen K.K.
- Location
- Australia;Canada;Iceland;United States of America;Denmark;Netherlands
Timeline & enrollment
- Phase
- N/A
- Start date
- N/A
- End date
- N/A
ICD-10 classifications
Cardiovascular disease, unspecifiedHypertensive heart diseaseHeart disease, unspecifiedAtherosclerotic cardiovascular disease, so describedAtherosclerotic heart disease
Data source
- Registry
- Japan Registry Clinical Trial
- Trial ID
- jRCT2031200367
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for jRCT2031200367 through Pure Global AI's free database. This phase not specified trial is sponsored by Amgen K.K. and is currently Completed. The study focuses on Cardiovascular Disease.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Japan Registry Clinical Trial data, helping medical device and pharmaceutical companies navigate clinical research efficiently.